Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxotere Prostate Cancer New Indication Registration Trial in China
NCT00436839Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2007
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sanofi. Started Jan 2007; status: completed.
02
Drugs
docetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00436839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436839.